Connect Biopharma’s (CNTB) Buy Rating Reaffirmed at HC Wainwright

Connect Biopharma (NASDAQ:CNTB)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $8.00 price target on the stock.

Connect Biopharma Trading Up 0.1 %

CNTB stock traded up $0.00 during midday trading on Monday, reaching $0.68. 31,912 shares of the company traded hands, compared to its average volume of 48,632. Connect Biopharma has a 52-week low of $0.67 and a 52-week high of $2.66. The business has a 50 day moving average of $0.90 and a 200-day moving average of $1.07.

Institutional Trading of Connect Biopharma

A number of institutional investors have recently bought and sold shares of CNTB. Callan Capital LLC raised its stake in shares of Connect Biopharma by 91.3% in the fourth quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock valued at $110,000 after acquiring an additional 38,177 shares during the period. Choreo LLC purchased a new stake in Connect Biopharma in the 4th quarter worth about $204,000. Finally, Catalina Capital Group LLC bought a new stake in Connect Biopharma in the fourth quarter worth about $66,000. 58.72% of the stock is currently owned by institutional investors.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.